Background Multisystem inflammatory syndrome in adults (MIS‐A) is a postacute coronavirus disease 2019 (COVID‐19) syndrome occurring weeks after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Although this hyperinflammatory syndrome causes significant morbidity, mortality is low. Reports of MIS‐A following acute respiratory distress syndrome (ARDS) due to SARS‐CoV‐2 infection have rarely been reported. We describe two cases of MIS‐A that developed after recovery from critical acute COVID‐19. Case Presentation We present two cases of MIS‐A. In both cases, approximately 4 weeks after the onset of COVID‐19, the patients developed gastrointestinal disorders, complicated by other organ damage, and died. Conclusion ARDS and MIS‐A can occur in a patient with COVID‐19 at different times of onset. Clinicians should consider MIS‐A when unexplained multisystemic abnormalities are noted after the treatment of ARDS due to COVID‐19.

In this study, the effect of sarpogrelate hydrochloride, a 5-hydroxytryptamine 2A receptor antagonist, on platelet aggregation at the site of injured carotid artery endothelium was examined. The rat common carotid artery was clamped for 30 min to induce endothelial injury. Sarpogrelate hydrochloride was administered before and after the injury, and the effects were compared with those in rats receiving sham operation only and those receiving clipping injury but no sarpogrelate hydrochloride. The animals were killed 24 h after the procedure. The common carotid artery was examined by scanning electron microscopy and stained immunochemically for factor VIII. Sarpogrelate hydrochloride treatment was associated with reduced aggregation of platelets on electron microscopy and lower expression of factor VIII at the injured intima. Sarpogrelate hydrochloride has an inhibitory effect on platelet aggregation at the intima in the acute stage after injury, suggesting that this drug may be used to prevent early ischaemic complications after surgical or endovascular arterial intervention.

The use of power‐injectable peripherally inserted central catheter (PIPICC) is a common practice, but displacement of these lines following injection of contrast media has been reported in 15.4% of cases. This report presents imaging evidence of displacement and self‐correction of a PIPICC line following contrast‐enhanced computed tomography.